{"filings":[{"id":948078,"accession_number":"0001213900-26-066896","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-06-09T21:26:27+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Bluejay Diagnostics shareholders approve 600K share increase in stock plan, authorize reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders re-elected all five directors: Chase, Dey, Dey, Wurth, Zeidman.","Approved amendment to 2021 Stock Plan, increasing authorized shares from 61 to 600,061.","Authorized reverse stock split at ratio 1:2 to 1:20; board has no present intention to implement in next 12 months.","Ratified Wolf & Company, P.C. as independent auditor for FY2026.","Stock closed at $4.50 on June 9, compliant with Nasdaq listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":920557,"accession_number":"0001213900-26-066364","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-06-08T21:15:17+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics closes $8.5M private placement with warrants for up to $23.7M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of 3,655,917 common shares (or pre-funded warrants) plus Series G and H warrants at $2.325/unit, raising $8.5M gross.","Net proceeds of ~$7.7M after placement agent fees; cash runway extended into Q1 2027, beyond expected FDA submission.","If all warrants exercised for cash, additional $15.2M proceeds would extend cash runway well beyond FDA approval and first year of commercialization.","Company must file resale registration statement by June 17, 2026 for underlying shares; warrants have exercise price $2.075."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":787197,"accession_number":"0001213900-26-063767","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-06-02T10:30:41+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics partners with Argonaut for US-based Symphony platform manufacturing","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Agreement with Argonaut for full manufacturing services (planning, sourcing, formulation, filling, QC, distribution) for IL-6 tests.","Partnership aims to establish scalable US-based manufacturing, reducing overseas dependency and import tariff risks.","Supports Symphony platform clinical programs (SYMON-I, II, III) and future commercialization in critical care near-patient testing.","No financial terms disclosed; platform remains investigational under US law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94835,"accession_number":"0001213900-26-053295","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bluejay Diagnostics Q1 2026: net loss $1.9M, SYMON-II study at 680 of 750 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents $3.7M as of Mar 31, 2026; net loss $1.9M unchanged YoY.","SYMON-II pivotal study enrollment at ~680 patients toward target of 750.","Resolved manufacturing issues with Sanyoseiko; progressing toward analytical/clinical validation.","Continuing FDA 510(k) strategy for Symphony IL-6 test after validation activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94834,"accession_number":"0001213900-26-040728","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics completes 624 of 750 patient enrollments in SYMON-II sepsis trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SYMON-II pivotal trial for Symphony IL-6 sepsis triage test enrolled 624 of 750 target patients.","Enrollment completion expected within 2-3 months, subject to site activity and patient flow.","Inclusion and exclusion criteria have not caused significant patient exclusions, per CEO Neil Dey."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107496,"accession_number":"0001213900-26-029261","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Bluejay Diagnostics raises $125,000 in private placement to insiders at $2.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 62,500 shares of common stock at $2.00 per share to five insiders, including CEO Neil Dey and Chair Donald Chase.","Gross proceeds of $125,000; sale closed on March 17, 2026, under Section 4(a)(2)/Reg D exemption.","No registration rights were granted; shares are restricted securities.","Proceeds likely used for general working capital; no other material terms disclosed.","All purchasers represented as accredited investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107495,"accession_number":"0001213900-26-027890","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bluejay acknowledges NorthStrive's acquisition suggestion, reiterates focus on Symphony platform","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Responds to NorthStrive Fund II LP letter proposing acquisition of Phase-1-ready chronic cough therapeutic program.","Board and management will evaluate the opportunity but emphasize current priorities: Symphony platform, SYMON II study, FDA submission.","Notes NorthStrive did not identify the potential counterparty; requests additional diligence information if available.","Reaffirms commitment to fiduciary duties under Delaware law and preserving cash resources."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107494,"accession_number":"0001213900-26-026749","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bluejay announces Symphony IL-6 Test abstract accepted for SAEM 2026 meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abstract accepted for presentation at Society of Academic Emergency Medicine Annual Meeting, May 18-21, 2026 in Atlanta.","Presentation reports SYMON-I pilot study data: IL-6 levels in ED linked to organ dysfunction (SOFA scores) in sepsis patients.","Principal investigator Nathan Shapiro: IL-6 measured in ED may be associated with subsequent organ dysfunction.","Ongoing SYMON-II pivotal study to validate IL-6 as prognostic biomarker for mortality, to support FDA 510(k) submission.","Company developing rapid near-patient Symphony IL-6 Test for sepsis triage and monitoring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107493,"accession_number":"0001213900-26-024352","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bluejay Diagnostics reports FY2025 net loss $6.8M; cash $5.2M; needs >$20M additional capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of ~$6.8M for FY2025; cash and cash equivalents $5.2M; stockholders' equity $6.0M as of Dec 31, 2025.","About 972,000 shares outstanding after full exercise of prefunded warrants; outstanding cash-exercisable warrants with strike above market.","SYMON II clinical study for IL-6 sepsis test progressing; data to support regulatory submission; limited disclosure before submission.","Manufacturing scale-up and supply-chain initiatives on track for commercialization readiness.","Company expects to need at least $20M additional capital through end of FY2027, to be raised in tranches."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107492,"accession_number":"0001213900-26-018638","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics: All prefunded warrants exercised; ~972K shares outstanding; 1.5M warrants at $7+","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All prefunded warrants from Oct 2025 private placement fully exercised as of Feb 19, 2026.","Common shares outstanding now ~972,000; no remaining prefunded warrants of any class.","Cash-exercisable warrants for ~1.5M shares outstanding, exercise price $7.00 or greater.","Notes recent 13G filings may not reflect 1-for-4 reverse split (Jan 29, 2026), overstating beneficial ownership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107491,"accession_number":"0001213900-26-017641","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics enrolls 545 patients in SYMON™ II study, exceeds expectations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrolled 545 of 750 target patients in SYMON™ II multicenter IL-6 monitoring study, exceeding initial expectations.","Completed monoclonal and polyclonal antibody production, providing capacity for >10 million test cartridges.","Manufacturing readiness includes cartridge characterization for U.S. commercial production and ongoing fabrication for FDA submission.","Company transitions focus to data analysis, regulatory engagement, and commercialization preparedness in 2026.","Technology transfer activities progress without single point of failure, mitigating scale-up risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107490,"accession_number":"0001213900-26-009792","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["3.03","5.03","5.07","8.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics implements 1-for-4 reverse stock split effective Jan 29, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-4 ratio; outstanding shares reduced from ~2,834,133 to ~708,533.","Shares from prefunded warrants reduced from 1,055,000 to 263,750; no fractional shares issued.","Common stock continues trading under symbol 'BJDX' on Nasdaq; new CUSIP 095633608.","Board approved final ratio on Jan 27, 2026; Certificate of Amendment filed with Delaware."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123848,"accession_number":"0001213900-25-126358","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics completes commercial-scale IL-6 antibody production for Symphony cartridges","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed commercial-scale production of polyclonal and monoclonal anti-IL-6 antibodies meeting internal performance criteria.","Antibodies intended for Symphony cartridge manufacturing for clinical and potential future commercial applications.","Sufficient material to support production of over 9 million Symphony cartridges; additional capacity established.","Symphony System remains under development, subject to further validation and FDA clearance before marketing.","Monoclonal antibodies designated as detection antibodies showed acceptable binding, specificity, and signal performance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123847,"accession_number":"0001213900-25-108192","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics Q3 update: SYMON-II 50% enrolled, $3.08M cash, needs $20M more by 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 cash $3.08M; stockholders' equity $3.69M. Raised $3.85M in April and $4.5M PIPE in October.","SYMON-II pivotal trial patient enrollment ~50% completed; sample testing expected late 2026 subject to financing.","Company expects to need at least $20M additional capital by end of FY2027 to fund operations and FDA submission.","Amended agreements with SanyoSeiko to expand manufacturing role for Symphony platform commercialization.","No revenue reported; pre-commercial stage; Symphony IL-6 test targets sepsis diagnostics, market projected at $1.8B by 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123846,"accession_number":"0001213900-25-098281","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics raises $4.5M in private placement of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $4.5M; net proceeds ~$4.0M after 8% placement agent fee and expenses.","Issued 2.25M shares/pre-funded warrants at $2.00/unit plus Series F warrants for 4.5M shares at $1.75.","Net proceeds to fund FDA approval efforts, clinical studies, R&D, and working capital.","Rodman & Renshaw acted as exclusive placement agent; warrants include 4.99%/9.99% beneficial ownership caps.","Company agreed to file resale registration statement by Oct 24, 2025, and has 90-day issuance lock-up post-effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123845,"accession_number":"0001213900-25-097564","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Bluejay expands SanyoSeiko partnership for Symphony platform commercialization","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["SanyoSeiko will serve as contract manufacturing organization for analyzers, cartridges, and components.","SanyoSeiko to oversee fulfillment, kit assembly, labeling, packaging, shipping, and quality control.","Partnership includes manufacturing redevelopment, raw material sourcing, vendor compliance, and regulatory support.","Bluejay's Symphony platform is a near-patient testing system for biomarkers like IL-6 in sepsis management.","No financial terms disclosed; Symphony not yet FDA cleared."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140514,"accession_number":"0001213900-25-077600","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bluejay Diagnostics announces Board chair and committee chair changes","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donald R. Chase appointed Chairperson of the Board, succeeding Douglas C. Wurth.","Douglas C. Wurth appointed Chairperson of Nominating and Corporate Governance Committee, succeeding Fred S. Zeidman.","Fred S. Zeidman appointed Chairperson of Compensation Committee, succeeding Donald R. Chase.","Chase remains Audit Committee Chair; all three independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140513,"accession_number":"0001213900-25-073870","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics Q2 update: SYMON-II enrollment starts, 510(k) target 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SYMON-II pivotal trial enrollment began; aims to validate IL-6 for 28-day mortality in ICU patients.","Raised $3.85M in April 2025 warrant inducement financing; anticipates more capital through 2027.","Amended Toray license extends cartridge manufacturing timeline to October 2026.","SanyoSeiko engaged as CMO for Symphony analyzer; cartridge redevelopment via FDA-registered CMO.","No detailed financial results disclosed; company pre-revenue with clinical and operational progress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140512,"accession_number":"0001213900-25-068296","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bluejay extends alternative manufacturing deadline by one year, pays $71k for final chip supply","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deadline to establish alternative manufacturing site for Symphony cartridges extended from Oct 2025 to Oct 2026.","Toray confirms all know-how provided; no further technical assistance obligations.","Bluejay to pay $71,212 to Toray for final supply of certain chip components.","Supply Agreement with Toray remains set to expire on October 23, 2025.","Failure to pay the $71k constitutes material breach; Toray may terminate license."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158216,"accession_number":"0001213900-25-055724","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bluejay Diagnostics shareholders approve reverse stock split of up to 1-for-20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected directors Chase, N. Dey, S. Dey, Wurth, Zeidman to 2026 term.","Approved reverse stock split at 1-for-2 to 1-for-20 ratio; board may implement within one year.","Approved additional reverse split (same ratio) contingent on first split being executed.","Ratified Wolf & Company as independent auditor for FY 2025.","Record date May 15, 2025; 616,134 shares voted from 1,494,182 outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158215,"accession_number":"0001213900-25-050913","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics mid-year update: cash $5.7M, headcount cut to 5, seeks $30M+ funding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SYMON-II pivotal sepsis trial enrolling; 510(k) submission planned for Q4 2027, FDA approval target Q3 2028.","Cash & equivalents $5.7M as of April 30, 2025; Q1 2025 net loss $1.9M, FY2024 net loss $7.7M.","April 2025 private placement raised $3.8M gross; company aims to raise at least $30M total through FY2027.","Workforce reduced to 5 employees after CTO departure; cost-saving measures implemented.","Annual meeting June 18, 2025: board to shrink from 6 to 5, reverse stock split proposals to maintain Nasdaq listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158214,"accession_number":"0001213900-25-048343","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bluejay Diagnostics CTO Jason Cook to depart on May 30; severance of 6 months salary plus pro rata bonus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CTO Jason Cook's employment ends May 30, 2025 under separation agreement.","Severance: $120,900 (6 months base salary) plus pro rata 2025 target bonus ($72,540).","Bonus prorated for days employed in 2025; paid in equal installments over 6 months.","Parties may later agree to consulting arrangement on mutually acceptable terms.","Separation treated as termination without cause; Cook retains certain covenants and cooperation obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158213,"accession_number":"0001213900-25-030312","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics raises ~$3.7M via warrant inducement; existing holders exercise at reduced price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered inducement agreements to exercise 1,085,106 Class C warrants at reduced exercise price of $3.42/share (down from $16.30).","Gross proceeds ~$3.7M; issued new Class E warrants for 1,085,106 shares exercisable at $3.42 through April 8, 2030.","Issued 682,203 common shares at closing; pre-funded warrants for 402,903 shares to avoid beneficial ownership limits.","Paid Aegis Capital Corp. $385,000 financial advisory fee; transaction closed April 8, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193429,"accession_number":"0001213900-24-105693","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bluejay Diagnostics regains Nasdaq minimum bid price compliance; deficiency closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Dec 3, 2024 confirming compliance with Rule 5550(a)(2).","Minimum bid price deficiency originally disclosed on March 4, 2024 is now closed.","Company's common stock (BJDX) remains listed on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193428,"accession_number":"0001213900-24-099327","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["3.03","5.03","5.07","8.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics implements 1-for-50 reverse stock split effective Nov 18, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduces outstanding shares from ~27.6M to ~552,854, no change to par value $0.0001.","No fractional shares; cash payment in lieu based on average closing price over ten days ending Nov 18.","Trading symbol BJDX unchanged; new CUSIP 095633509.","Proportionate adjustments to all outstanding equity awards and warrants.","Stockholders with certificates receive instructions from exchange agent Continental Stock Transfer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193427,"accession_number":"0001213900-24-090120","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bluejay Diagnostics shareholders approve reverse stock split (1:20-1:50 ratio)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["6,958,210 shares present (42.0% quorum) at October 23, 2024 special meeting.","Proposal passed: 5,358,166 For, 1,487,443 Against, 112,601 Abstain.","Board retains discretion to select exact ratio (1:20 to 1:50) and timing.","No decision yet on whether or when to implement the reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193426,"accession_number":"0001213900-24-088196","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Bluejay Diagnostics reduces stockholder meeting quorum threshold to one-third","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Amendment No. 1 to Bylaws reducing quorum from majority to one-third of shares entitled to vote.","Amendment effective immediately upon Board adoption on October 16, 2024.","Change intended to lower the share-count required to hold valid stockholder meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209749,"accession_number":"0001213900-24-073437","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["3.01","5.03","8.01","9.01"],"status":"ready","headline":"Delisting extension and massive warrant dilution for Bluejay Diagnostics (BJDX); authorized shares up to 250M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq extended compliance deadline to Feb 24, 2025; stock must close at $1.00+ for 10 days.","Stockholders approved increase in authorized common shares from 50M to 250M.","Class D warrants exercisable for ~21.5M shares at $0.0001; 6.6M shares issued so far.","Class C warrants exercise price reset from $1.96 to $0.326, increasing potential dilution.","Outstanding shares as of Aug 27: 12.85M; significant dilution expected from warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209748,"accession_number":"0001213900-24-071394","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve increase in authorized shares and warrant issuance at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal to increase authorized common stock shares passed: 223,019 for, 32,958 against, 45,001 abstain.","Proposal 2: shareholders approved issuance of Class C warrants from June 28, 2024 offering (144,962 for).","Proposal 3: shareholders approved issuance of Class D warrants from same offering (144,881 for).","Quorum achieved with 300,978 shares (53.4%) present; Proposal 4 on adjournment not acted upon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227923,"accession_number":"0001213900-24-057240","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics closes $8.75M public offering to repay debt and fund FDA work","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $8.75M from sale of 5,368,098 units at $1.63/unit.","Units consist of 1 share (or pre-funded warrant), 2 Class C warrants, 1 Class D warrant.","Net proceeds to repay $2.3M debt and fund FDA approval (incl. clinical studies), R&D, working capital.","Class C warrants ($1.96 strike, 5-year term) require stockholder approval to become exercisable.","Underwriting discount 8.5%; Aegis Capital Corp. acted as sole underwriter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227922,"accession_number":"0001213900-24-054284","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["3.03","5.03","5.07","8.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics announces 1-for-8 reverse stock split effective June 20, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-8 ratio effective 12:01 a.m. ET on June 20, 2024.","Outstanding shares reduced from ~4,511,756 to ~563,969; no fractional shares issued.","Fractional shareholders receive cash payment based on average closing price over 10 trading days ending June 17.","Ticker BJDX unchanged; new CUSIP 095633400; equity awards and warrants adjusted proportionately.","Continental Stock Transfer is exchange agent; book-entry holders need no action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227921,"accession_number":"0001213900-24-048546","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Bluejay Diagnostics raises $2M in senior secured notes with equity kicker","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered NPA for $1M note (repayable $1,176,470) and SPA for $1M notes plus 580,308 shares, both due Sept 2024.","First lien security interest granted on substantially all assets; closings expected June 3, 2024.","Must file registration statement within 14 days and complete public offering within 90 days, or default.","Aegis Capital Corp. served as placement agent for the transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227920,"accession_number":"0001213900-24-044034","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Bluejay Diagnostics increases authorized shares from 7.5M to 50M; shareholders approve reverse stock split up to 1:10","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized shares of common stock increased from 7,500,000 to 50,000,000 via amendment filed May 14, 2024.","Stockholders approved reverse stock split at ratio of 1-for-2 to 1-for-10; board to decide final ratio and timing.","Directors Donald Chase, Neil Dey, Svetlana Dey, Fred Zeidman, Gary Gemignani, and Douglas Wurth re-elected.","Ratification of Wolf & Company, P.C. as independent auditor for FY2024 approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227919,"accession_number":"0001213900-24-029411","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Bluejay Diagnostics terminates interim CFO; CEO assumes principal financial officer role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Frances Scally ceased as Interim CFO effective March 29, 2024, following termination of DLA agreement.","CEO Neil Dey designated as principal financial and accounting officer in addition to CEO role.","2024 annual meeting scheduled for May 14, 2024; record date set as April 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246692,"accession_number":"0001213900-24-019210","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bluejay Diagnostics receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price below $1.00 for 30 consecutive business days; non-compliance with Nasdaq Listing Rule 5550(a)(2).","Company has 180 days, until August 26, 2024, to regain compliance by closing at $1.00+ for ten consecutive days.","If not cured, Company may be eligible for additional 180-day period, but delisting risk exists if unable to comply.","Company intends to take reasonable measures to regain compliance but no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246691,"accession_number":"0001213900-24-000317","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics closes $3.5M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2,692,308 units sold at $1.30/unit: one share (or pre-funded warrant) plus one warrant to buy one share.","Gross proceeds ~$3.5M; net proceeds to fund FDA approval, clinical studies, R&D, and working capital.","Warrants exercisable at $1.30/share for 5 years; pre-funded warrants exercisable at $0.0001.","H.C. Wainwright as placement agent; 7% cash fee and 188,462 placement agent warrants at $1.625.","Offering closed Jan 2, 2024; registered on Form S-1 effective Dec 27, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264123,"accession_number":"0001213900-23-098726","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2023-12-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bluejay initiates SYMON multicenter study of Symphony IL-6 test in sepsis patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study will monitor IL-6 in sepsis/septic shock patients admitted to ICU; aims to predict 28-day mortality.","Study design incorporates feedback from pre-submission meetings with the FDA held earlier in 2023.","Symphony System delivers results from whole blood in ~20 minutes; study listed on clinicaltrials.gov (NCT06181604).","CEO Neil Dey says study moves company 'one step closer to commercialization' and may identify competitive advantages."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264122,"accession_number":"0001213900-23-085197","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bluejay Diagnostics Q3 net loss $2.29M; Toray license cut to 7.5% royalty","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.29M ($2.08/share) for Q3 2023; nine-month loss $7.65M ($7.30/share).","Cash $5.08M as of Sep 30, 2023, down from $10.1M; expects funding into Q1 2024, needs more capital.","Renegotiated Toray license: royalty reduced from 15% to 7.5% for 10 years; 50% reduction after patent expiry.","Plans to submit FDA 510(k) for Symphony IL-6 in first half 2024 based on August 2023 feedback.","Also renegotiated supply agreement with Toray for cartridge component supply for clinical studies."],"consensus_eps_estimate":-1330.08,"consensus_eps_actual":-7.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264121,"accession_number":"0001013762-23-006952","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics amends Toray license; royalty cut to 7.5% of net sales, supply deal for FDA path","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Royalty rate reduced from 15% to 7.5% of net sales (or less) for 10-year term; 50% reduction after patent expiry.","New supply agreement: Toray will manufacture intermediates for FDA-approval cartridges through Oct 2025 or FDA clearance.","Bluejay obtains right to sublicense Toray IP to Sanyoseiko for manufacturing Symphony device and cartridges for clinical trials.","Technology transfer from Toray to Sanyoseiko for cartridge manufacturing, enabling commercial scale production.","Prior upfront license fee of $240,000 already paid; post-commercial minimum annual royalty of $100,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264120,"accession_number":"0001013762-23-003985","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bluejay Diagnostics separates from Kenneth R. Fisher with $240K severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kenneth R. Fisher separated from employment on Sept 26, 2023; separation agreement effective Oct 14.","Severance of $240,000 aggregate (6 months base salary plus pro rata 2023 target bonus).","Payment subject to confidentiality, cooperation, and other ongoing covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264119,"accession_number":"0001013762-23-000463","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bluejay Diagnostics CFO Kenneth Fisher departs; Frances Scally named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kenneth R. Fisher ceased as CFO on September 26, 2023; may receive severance per employment agreement.","Frances Scally, age 56, appointed interim CFO, principal financial officer and principal accounting officer.","Scally is an employee of DLA LLC; services provided under a scope of work agreement on an hourly basis.","Scott Levy of DLA also appointed as a special advisor to the CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281370,"accession_number":"0001213900-23-071272","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2023-08-28T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Bluejay Diagnostics announces $1.59M registered direct offering and warrant private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered definitive agreement for registered direct offering of 216,000 shares at $7.365/share, raising ~$1.59M gross.","Concurrent private placement of warrants to purchase 216,000 shares at $7.24/share, exercisable for 5 years.","Proceeds intended for FDA approval activities, clinical studies, R&D, and general working capital.","H.C. Wainwright & Co. acted as exclusive placement agent; closing expected August 28, 2023.","Warrants and underlying shares sold unregistered under Section 4(a)(2) and Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281369,"accession_number":"0001213900-23-067990","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2023-08-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bluejay Diagnostics H1 2023 net loss $5.4M; cash down to $5.1M; FDA meeting on IL-6 test","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.4M ($5.24/sh) vs $4.0M ($2.00/sh) in H1 2022; no revenue reported.","Cash and equivalents fell to $5.1M from $10.1M at Dec 31, 2022; company expects to raise capital near-term.","R&D expense doubled to $3.0M, driven by clinical trial costs for Symphony IL-6 sepsis test.","FDA pre-submission meeting on Aug 11, 2023 confirmed 510(k) pathway; company targets submission in H1 2024.","Sales and marketing expense $302K vs $135K in prior period as company builds commercial infrastructure."],"consensus_eps_estimate":-2448.0,"consensus_eps_actual":-5.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281368,"accession_number":"0001213900-23-065581","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics regains Nasdaq minimum bid price compliance after reverse stock split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notification on Aug 8, 2023 that minimum bid price deficiency is closed.","Reverse stock split executed on July 24, 2023 to help regain compliance.","Closing bid price was at least $1.00 for ten consecutive business days.","Original deficiency was reported on October 25, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281367,"accession_number":"0001213900-23-058659","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2023-07-21T23:59:59+00:00","items":["3.03","5.03","5.07","8.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics announces 1-for-20 reverse stock split to meet Nasdaq minimum bid price, effective July 24, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-20; authorized shares reduced from 100M to 7.5M; outstanding shares from ~20.5M to ~1.02M.","Effective 12:01 a.m. ET July 24, 2023; shares trade post-split on Nasdaq under same symbol BJDX with new CUSIP 095633301.","Split ensures compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing.","No fractional shares issued; cash payment in lieu based on ten-day average closing price.","Outstanding warrants and equity awards adjusted proportionally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300165,"accession_number":"0001213900-23-049894","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bluejay Diagnostics shareholders approve reverse stock split, elect directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected six directors: Wurth, N. Dey, S. Dey, Chase, Zeidman, Gemignani; each received >10.6M votes for.","Approved amendment to certificate of incorporation to effect reverse stock split; 12.79M for, 714k against.","Ratified Wolf & Company, P.C. as independent auditor for FY 2023; 13.38M for, 88k against.","Quorum of 67.2% (13.75M shares) present at meeting held June 14, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300164,"accession_number":"0001213900-23-041332","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics updates Symphony IL-6 regulatory strategy, expands trial to sepsis patients","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Trial widened from severe COVID-19 only to all hospitalized sepsis patients to speed enrollment while maintaining H1 2024 submission timeline.","Company to submit FDA pre-submission application for revised study design in Q2 2023.","New indication for risk stratification of hospitalized sepsis patients aligns with recent FDA feedback."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300163,"accession_number":"0001213900-23-037951","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bluejay Diagnostics Q1 net loss $2.5M, cash $6.8M; focuses on FDA pathway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.5M ($0.12/shr) vs $2.0M ($0.10/shr) in Q1 2022.","Cash and equivalents fell to $6.8M at March 31, 2023 from $10.1M at Dec 31, 2022.","R&D expense rose to $1.4M from $695k, driven by clinical trial and personnel costs.","CEO notes resources aligned with FDA feedback to optimize Symphony IL-6 approval pathway.","No revenue reported; pre-commercial stage diagnostics company."],"consensus_eps_estimate":-1958.4,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300162,"accession_number":"0001213900-23-033248","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq grants Bluejay Diagnostics extension to Oct 23, 2023 to regain $1 bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company received original deficiency notice on Oct 25, 2022 for bid price below $1.","Nasdaq extended compliance deadline to Oct 23, 2023; must close at $1+ for 10 consecutive days.","Company may implement a reverse stock split, subject to stockholder approval, to regain compliance.","If not compliant by deadline, Nasdaq will delist the stock; appeal rights available.","No assurance of regaining or maintaining compliance with Nasdaq listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320221,"accession_number":"0001213900-23-021408","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2023-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bluejay Diagnostics reports 2022 net loss $9.3M; FDA submission delayed to H1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.3M ($0.46 per share) vs $3.5M ($0.41 per share) in 2021.","Cash and cash equivalents $10.1M, down from $19.0M year-over-year.","R&D expense increased 262% to support clinical trials for planned FDA submission.","FDA feedback requires expanded clinical study; de novo submission timeline pushed to H1 2024.","Company to require additional funding to reach commercialization due to delay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2234881.121841432,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-03-20T23:59:59+00:00|320221"}